Rapid progress on MDD (Medical Devices Directive) review at Council and Parliament levels
This article was originally published in Clinica
Executive Summary
Swift progress is already being made at the European Council on discussions on the proposed review of the Medical Devices Directive. A meeting, scheduled for February 20, will allow the Council to complete its first preliminary review of the text, before a second round of discussions is launched. This review at the Council is allowing major issues to be identified where there is not full agreement. It gives the EU presidency, currently held by Austria, as well as expert working groups or committees that have been set up by member states on particular subjects, an opportunity to contribute to the debate. The Commission can also propose some redrafting where necessary. In parallel, there have also been developments at the European Parliament. The EP has decided is to consult the European Economics and Social Committee (Ecosoc) over the text. And Ecosoc has appointed Paolo Braghin, of Italian industry association Confindustria, as rapporteur.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.